United Therapeutics pays $525 million to buy out Pfizer royalty on ralinepag
United Therapeutics announced an amendment to its license with Pfizer’s Arena subsidiary that removes all royalty obligations on the pulmonary‑arterial‑hypertension drug ralinepg. The company will make a single upfront payment of $525 million. The FDA is reviewing a new drug application for the oral formulation, with a decision expected in June 2027, and United Therapeutics continues to develop an inhaled version.
Why it matters
The buyout eliminates a double‑digit royalty on future net sales, allowing United Therapeutics to retain the full revenue stream if ralinepg is approved. The $525 million cash outlay is a material expense but may improve profitability of the product once commercialized.
Key facts
- 1United Therapeutics will pay $525 million to Pfizer’s Arena subsidiary to terminate royalty obligations on ralinepg. finance.yahoo.com
- 2The royalty removal applies to all oral and inhaled formulations of ralinepg. finance.yahoo.com
- 3The FDA has scheduled a decision on the oral ralinepg NDA for June 24 2027. investing.com
- 4United Therapeutics acquired exclusive rights to ralinepg in 2018 under a license with Arena. finance.yahoo.com
- 5The company still faces contingent milestone payments of $250 million for the first U.S. approval of an inhaled version and $150 million for the first approval of an oral version in selected foreign markets, totaling $400 million. citybiz.co
- 6United Therapeutics reported Q3 2026 revenue of $832.5 million, a 4 % year‑over‑year increase. tradingview.com
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.